Compounds for use in treatment or prophylaxis of pain, inflammation and / or autoimmunity

Abstract

To provide compounds for use in treatment or prophylaxis of pain, inflammation and / or autoimmunity.SOLUTION: The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)-1-(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to treatment or prophylaxis of pain, inflammation and / or autoimmunity and provides a method of treating or preventing pain, inflammation and / or autoimmunity as well as use of this polymorphic form in manufacture of medicaments for the treatment or prophylaxis of pain (preferably nociceptive or neuropathic), inflammation and / or autoimmunity in humans and / or non-human animals.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a polymorph of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or synonymously N-[2-(4-hydroxy-phenyl)-1-(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to a method for treating or preventing pain, inflammation and / or autoimmunity and to the use of this polymorph in the manufacture of a medicament for the treatment or prevention of pain (preferably nociceptive or neuropathic), inflammation and / or autoimmunity in humans and / or non-human animals. [Background technology]

[0002] background The compound 2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide has been disclosed in US 7,754,771 and its use in the treatment or prevention of pain and inflammation has been disclosed in WO 2009 / 1099850, WO 2011 / 030105, US 2011 / 0086910 and WO WO 2013 / 084238 has described this compound. Previous disclosures of this compound related to a racemate containing all four enantiomers and diastereomers, i.e., (S,S), (S,R), (R,R) and (R,S). WO 2013 / 084238 noted that the racemate containing the S enantiomer at the chiral position adjacent to the amide exhibited particularly advantageous properties.

[0003] Pain is a multifaceted or multidimensional experiential response to a variety of stimuli conditions. Pain is defined by the International Association for the Study of Pain (IASP) as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage."

[0004] Pain in animals is often the result of nociception, i.e. activity in the nervous system resulting from stimulation of nociceptors. Neuropathic pain differs from nociceptive pain in that it involves damage to the nerves that produce the sensation of pain. In central pain, the pain originates in the brain from some form of lesion. Sometimes pain is psychogenic, i.e. caused by a mental illness.

[0005] Pain can be acute or chronic. Acute pain is usually caused by soft tissue injury, infection and / or inflammation, among other causes. Acute pain acts as a warning after a physical injury or dysfunction. Chronic pain may have no apparent cause and may be caused by an underlying illness or imbalance. Chronic pain is defined as a pain disorder; its origin, duration, intensity and specific symptoms may vary.

[0006] Physiological pain experiences can be grouped according to the source and associated nociceptors. Cutaneous pain is caused by injury to the skin or superficial tissue. Cutaneous nociceptors terminate just beneath the skin and are highly concentrated with nerve endings, resulting in well-defined, localized pain of short duration. Examples of injuries that produce cutaneous pain include paper cuts, small cuts, small (first degree) burns and lacerations. Somatic pain originates in ligaments, tendons, bones, blood vessels and nerves. It is detected by somatic nociceptors. A deficiency of pain receptors in these areas results in a dull, poorly-localised pain of longer duration than cutaneous pain; examples include sprains and fractures. Myofascial pain is usually caused by trigger points in muscles, tendons and fascia and may be localised or referred. Visceral pain originates in an internal organ or viscera of the body. Visceral nociceptors are located inside the organs and cavities of the body. A greater lack of nociceptors in these areas results in pain that is usually more painful and of longer duration than somatic pain. Visceral pain is extremely difficult to localize, and some damage to visceral tissues exhibits "referred" pain, where the sensation is located in an area completely unrelated to the site of injury. Phantom limb pain is a type of referred pain, a sensation of pain from a limb that has been lost or from which the individual no longer receives physical signals. Neuropathic pain can occur as a result of injury or disease to the nerve tissue itself. This can disrupt the ability of sensory nerves to transmit accurate information to the thalamus, so the brain interprets painful stimuli even when there is no obvious psychological cause for the pain.

[0007] Acute pain is usually treated simultaneously with medicines or suitable techniques to remove its cause and to control the sensation of pain (generally analgesics).

[0008] Analgesics are divided into three categories: opioid (narcotic) analgesics, nonopioid analgesics and adjuvant analgesics. Opioid analgesics are powerful painkillers chemically related to morphine. However, opioids have many side effects, which are more likely to occur in people with certain disorders: renal failure, liver damage, chronic obstructive pulmonary disease (COPD), dementia or another brain disorder. Drowsiness, constipation, nausea, vomiting and pruritus are common when opioids are started. Apart from morphine, the opioid analgesics known at the time of writing include codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, oxycodone, oxymorphone, pentazocine and propoxyphene.

[0009] A variety of non-opioid analgesics are also available at the time of writing. They are often effective for mild to moderate pain. Most non-opioid analgesics are classified as non-steroidal anti-inflammatory drugs (NSAIDs). An example of an analgesic that is not an NSAID is acetaminophen, which is commonly known as paracetamol. Acetaminophen has virtually no anti-inflammatory properties.

[0010] NSAIDs are used to treat mild to moderate pain, and can be combined with opioids to treat moderate to severe pain. NSAIDs not only reduce pain, but also reduce the inflammation that often accompanies and exacerbates pain. Although widely used, NSAIDs can also have side effects, sometimes serious, including problems in the digestive tract, bleeding problems, problems with fluid retention, and increased risk of heart and vascular disorders. Current NSAIDs include aspirin, ibuprofen, ketoprofen, naproxen, cox-2 inhibitors (e.g., celecoxib), choline magnesium trisalicylate, diflunisal, salsalate, diclofenac, etodolac, fenoprofen, flurbiprofen, indomethacin, ketorolac, meclofenamate, meclofenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, and tolmetin.

[0011] Adjunctive analgesics include antidepressants (such as imipramine, amitriptyline, bupropion, desipramine, fluoxetine and venlafaxine); anticonvulsants (such as carbamazepine, gabapentin and pregabalin) and oral and local anesthetics.

[0012] In the treatment of chronic pain, the "three-step pain relief ladder" established by the World Health Organization is often used. For mild pain, acetaminophen, aspirin or other NSAIDs can be used. For mild to moderate pain, weak opioids (e.g., codeine and dihydrocodeine) are used in combination with acetaminophen, aspirin or other NSAIDs. In the case of moderate to severe pain, strong opioids (e.g., morphine, diamorphine, or fentanyl, hydromorphone, methadone, oxycodone or phenazocine) can be administered in combination with acetaminophen, aspirin or other NSAIDs. Currently available treatments for neuropathic pain have only low to moderate effectiveness, leaving many patients without significant pain relief. Millions of people with neuropathic pain, as well as people with other types of pain, lack adequate pain relief, indicating a large unmet medical need, which the present invention addresses. [Prior art documents] [Patent documents]

[0013] [Patent Document 1] U.S. Pat. No. 7,754,771 [Patent Document 2] International Publication No. 2009 / 1099850 [Patent Document 3] International Publication No. 2011 / 030105 [Patent Document 4] US Patent Application Publication No. 2011 / 0086910 [Patent Document 5] International Publication No. 2013 / 084238 Summary of the Invention [Means for solving the problem]

[0014] Summary of the Invention The present invention relates to a polymorph of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide and to a method of treating or preventing pain, inflammation and / or autoimmunity, and to the use of this polymorph in the manufacture of a medicament for the treatment or prevention of pain (preferably nociceptive or neuropathic), inflammation and / or autoimmunity in humans and / or non-human animals. More specifically, the compound used in the present invention has the following chemical formula: [ka] which is the (S,S)-isomer of 2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide.

[0015] The present invention relates to a polymorph of this compound. The polymorph of this compound is used in the present invention. This polymorph (hereinafter also referred to as polymorph 2) can be characterized by methods such as X-ray, DSC and / or Raman spectroscopy.

[0016] Polymorph 2 has surprisingly been found to be less hygroscopic, more stable and more readily bioavailable than other crystalline forms (eg, Polymorph 1), as discussed below. In an embodiment of the present invention, for example, the following items are provided: (Item 1) formula: [ka] A polymorph of a compound having the formula: wherein the polymorph has an X-ray powder diffraction pattern (CuKα) including a peak at 19.0±0.2 degrees 2θ. (Item 2) The polymorph according to item 1, wherein the polymorph has a melting point in the range of about 105°C to about 110°C. (Item 3) formula: [ka] A polymorph of a compound having the formula: Here, the polymorph has a melting point in the range of about 105°C to about 110°C. (Item 4) 4. The polymorph according to claim 3, wherein the polymorph has an X-ray powder diffraction pattern (CuKα) comprising a peak at about 19.0±0.2 °2θ. (Item 5) 5. The polymorph of any one of items 1 to 4, wherein the X-ray powder diffraction pattern (CuKα) further comprises one or more peaks selected from peaks at 11.25±0.2, 17.38±0.2, 17.57±0.2, 20.74±0.2, 20.91±0.2, 22.42±0.2 and 23.30±0.2 °2θ. (Item 6) 6. The polymorph according to any one of items 1 to 5, wherein the X-ray powder diffraction pattern (CuKα) is substantially as shown in FIG. (Item 7) 7. The polymorph according to any one of items 1 to 6, wherein the polymorph has a melting point in the range of about 106°C to about 109°C, preferably about 107°C to about 108°C. (Item 8) 7. The polymorph according to any one of items 1 to 6, wherein the polymorph has a melting enthalpy in the range of 100 J / g to 140 J / g, preferably 110 J / g to 130 J / g and more preferably 115 to 125 J / g. (Item 9) 9. The polymorph according to any one of items 1 to 8 for use as a medicament. (Item 10) 9. The polymorph according to any one of items 1 to 8 for use in the treatment or prevention of pain. (Item 11) 9. The polymorph according to any one of items 1 to 8 for use in the treatment or prevention of inflammation and / or autoimmunity. (Item 12) A pharmaceutical composition for use in the treatment or prevention of pain, inflammation and / or autoimmunity, said composition comprising a pharma- ceutical effective amount of one or more of the compounds according to any one of items 1 to 8, optionally together with one or more pharma- ceutical acceptable excipients. (Item 13) 13. The pharmaceutical composition according to item 12, wherein the composition is formulated as a unit dosage form and preferably contains from 0.1 to about 500 mg of the one or more compounds. (Item 14) 14. The pharmaceutical composition according to item 12 or 13, which is administered orally. (Item 15) A method for treating or preventing pain, inflammation and / or autoimmunity in a human or non-human animal patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound according to any of items 1 to 8 or a pharmaceutical composition according to item 12 or 13. (Item 16) 16. The method according to item 15, wherein a daily dose of 0.1 mg to 15 g of the one or more compounds is administered. (Item 17) 17. The method of claim 15 or 16, wherein the one or more compounds are administered orally. [Brief description of the drawings]

[0017] [Figure 1] Figure 1: X-ray powder diffraction pattern of polymorph 2 [Diagram 2] Figure 2: SEM image of polymorph 2. [Diagram 3] Figure 3: Raman spectrum of polymorph 2 measured on a Bruker RFS 100 / S at 1064 nm. [Figure 4] Figure 4: TGA / DTA data for polymorph 2. [Diagram 5] Figure 5: Analytical data sheet for polymorph 1. [Figure 6] Figure 6: Analytical data sheet for polymorph 2. [Figure 7] Figure 7: Pre-dose body weights and calculated doses of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) following oral administration of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) to male beagle dogs at a target dose level of 60 mg / kg. [Figure 8]Figure 8: Actual blood sampling times following oral administration of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) at the target dose level of 60 mg / kg at week 2. [Figure 9] Figure 9: Mean and individual plasma concentrations of NRD135S.E1 following oral administration of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) at a target dose level of 60 mg / kg. [Figure 10] Figure 10: Mean and individual pharmacokinetic parameters of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) in male beagle dog plasma following oral administration at a nominal dose of 60 mg / kg at week 1. [Figure 11] Figure 11: Mean and individual pharmacokinetic parameters of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) in male beagle dog plasma following oral administration at a nominal dose of 60 mg / kg at week 2. [Figure 12] FIG. 12: Mean plasma concentrations of NRD135S.E1 Form 1 (141232) and Form 2 (COEN4-091-M) in male beagle dogs following oral administration at a nominal dose of 60 mg / kg. [Figure 13] Figure 13: Individual plasma concentrations of NRD135S.E1 form 1 (141232) in male beagle dogs following oral administration of a nominal dose of 60 mg / kg (sequence 1-1 old). [Figure 14] Figure 14: Individual plasma concentrations of NRD135S.E1 form 2 (COEN4-091-M) in male beagle dogs following oral administration at a nominal dose of 60 mg / kg (sequence 2-1 new). [Figure 15] Figure 15: Individual plasma concentrations of NRD135S.E1 form 2 (COEN4-091-M) in male beagle dogs following oral administration at a nominal dose of 60 mg / kg (sequence 1-2 new). [Figure 16]Figure 16: Individual plasma concentrations of NRD135S.E1 form 1 (141232) in male beagle dogs following oral administration at a nominal dose of 60 mg / kg (sequence 2-2 old). [Figure 17] Figure 17: 1H-NMR spectrum of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description of the Invention The present invention relates to a polymorph of a specific compound and to a method of treating or preventing pain, inflammation and / or autoimmunity, and provides the use of the polymorph in the manufacture of a medicament for the treatment or prevention of pain (preferably nociceptive or neuropathic), inflammation and / or autoimmunity in humans and / or non-human animals. More specifically, the compound used in the present invention has the following chemical formula: [ka] It is a compound of the formula:

[0019] This compound ((S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide), including its enantiomers and diastereomers, can be prepared as described in WO 2013 / 084238, which is incorporated herein by reference, in particular in Examples 1 and 2 thereof.

[0020] The ((S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide) used in the present invention is preferably an enantiomer that is substantially free of other stereoisomeric forms of the compound. A representative substantially pure enantiomer contains more than 90% by weight of one enantiomer of the compound and less than 10% by weight of other stereoisomeric forms of the compound, preferably more than 95% by weight of one enantiomer of the compound and less than 5% by weight of other stereoisomeric forms of the compound, and even more preferably more than 98% by weight of one enantiomer of the compound and less than 2% by weight of other stereoisomeric forms of the compound. The term "other stereoisomeric forms" typically refers to the (S,R), (R,S) and (R,R) enantiomeric or diastereomeric forms of the compound 2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide. The substantially pure (S,S)-enantiomer can activate BLK and LynA tyrosine kinases, while having no or substantially no effect on the activity of LynB tyrosine kinase.

[0021] A polymorph of this compound is used in the present invention. This polymorph, hereinafter also referred to as polymorph 2, may be characterized by methods such as X-ray, DSC and / or Raman spectroscopy.

[0022] The inventors have surprisingly found that polymorph 2 is less hygroscopic and more stable than other crystalline forms (e.g., polymorph 1, as discussed hereinafter). Furthermore, polymorph 2 has surprisingly been found to have better bioavailability compared to polymorph 1. This is particularly surprising in light of its greater stability. Thermal analysis of polymorph 2 shows a melting point with an onset at 104.5°C and a melting peak at 107.2°C. Its enthalpy of melting ΔH melt was approximately 121 J / g.

[0023] Thermal analysis to determine the melting point and enthalpy of fusion of the claimed polymorphs is performed using a TGA / DTA analyzer (e.g., a Perkin-Elmer STA 600 TGA / DTA analyzer) at a temperature of 25° C. at a rate of 10° C. / min, typically at 25° C. The procedure may be carried out by heating the sample from 200 to 300° C. during which time the weight change is monitored along with the differential thermal analysis (DTA) signal while the purge gas used is 20 cm 3 / min flow rate of nitrogen.

[0024] Scanning electron microscopy (SEM) shows that polymorph 2 has a regular rectangular block crystal habit with grains ranging in size from 2 to 10 μm long and 2 to 5 μm wide. The grain size is typically measured using laser diffraction, D 50 It is expressed as the volume median particle size.

[0025] Gravimetric Vapour Sorption (GVS) indicates that polymorph 2 is very slightly hygroscopic with a weight gain of 0.6% up to 80% RH.

[0026] The polymorph 2 of the present invention may be isolated by preparing a slurry in water and crystallizing from a 50 / 50 mixture of methanol and water by weight. It may also be prepared by rapidly cooling the solution in chloroform and isopropyl acetate.

[0027] Polymorph 2 of the present invention typically has an X-ray powder diffraction pattern (CuKα) comprising a peak at 19.0±0.2 °2θ, more preferably at 19.0±0.1 °2θ and even more preferably at 19.0±0.05 °2θ. More preferably, the polymorph has an X-ray powder diffraction pattern (CuKα) further comprising one or more peaks selected from peaks at 11.25±0.2, 17.38±0.2, 17.57±0.2, 20.74±0.2, 20.91±0.2, 22.42±0.2 and 23.30±0.2 °2θ. Said further peak is even more preferably selected from 11.25±0.1, 17.38±0.1, 17.57±0.1, 20.74±0.1, 20.91±0.1, 22.42±0.1 and 23.30±0.1 °2θ. Even more preferably said peak is selected from 11.25±0.05, 17.38±0.05, 17.57±0.05, 20.74±0.05, 20.91±0.05, 22.42±0.05 and 23.30±0.05 °2θ. Preferably said peak at 19.0±0.2 °2θ, more preferably at 19.0±0.1 °2θ, is the peak with the highest relative intensity (particularly in the range of 5-40 °2θ) in the X-ray powder diffraction pattern (CuKα) of polymorph 2.

[0028] Polymorph 2 preferably does not contain any peaks within the ranges of 15±0.3° 2θ and 16.5±0.2° 2θ. More preferably, Polymorph 2 does not contain any peaks within the ranges of 15±0.5° 2θ and 16.5±0.3° 2θ.

[0029] Even more preferably, the X-ray powder diffraction pattern (CuKα) of polymorph 2 of the present invention is substantially as shown in FIG.

[0030] Polymorph 2 typically has a melting point in the range of about 105° C. to about 110° C. More preferably, the melting point is in the range of about 106° C. to about 109° C., preferably about 107° C. to about 108° C.

[0031] In addition to the above, it is even more surprising that in a dog bioavailability study, the bioavailability of the polymorph 2 of the present invention was found to be exceptionally high, in particular higher than that of polymorph 1, as described in the experimental data described herein.

[0032] In contrast, polymorph 1 is characterized by a higher hygroscopicity and a lower stability than polymorph 2 of the present invention. Shows.

[0033] Thus, thermal analysis of polymorph 1 shows a melting point with onset at 119.6° C. and a melting peak at 125.6° C. Its enthalpy of fusion ΔH melt was approximately 19 J / g.

[0034] Simultaneous thermal analysis (STA) data for polymorph 1 further indicates a small weight loss of just under 1% between 90 and 115° C., followed by melting in a single thermal event with an onset at about 119.5° C. Polymorph 1 may therefore be a partial hydrate.

[0035] Scanning electron microscopy (SEM) shows that polymorph 1 has mostly irregularly shaped particles less than 10 μm in width.

[0036] Gravimetric vapor sorption (GVS) indicates that polymorph 1 is hygroscopic, with a weight increase of about 1.3% up to 70% RH. However, a rapid water uptake occurs at 70-80% RH. Between RHs, continuing to 5.6%, there was a hysteresis (gap) between the sorption and desorption cycles, suggesting a morphology change. This different morphology appeared to be more hygroscopic. The second sorption cycle shows a weight gain well above the 2% satisfaction limit at just 40% RH.

[0037] Polymorph 1 can be prepared by recrystallization from various solvents such as methanol, ethanol, 2-propanol, acetonitrile, acetone, 1,4-dioxane, and dimethylformamide.

[0038] medical use The present invention also relates to polymorph 2 for use as a medicament and for use in the treatment or prevention of a disease selected from pain, inflammation and autoimmunity. The disease is preferably pain.

[0039] Additionally encompassed by the present invention are pharmaceutical compositions for use in the treatment or prevention of pain, inflammation and / or autoimmunity, said compositions comprising a pharma- ceutical effective amount of Polymorph 2, optionally together with one or more pharma- ceutical acceptable excipients. Pharmaceutical compositions of the present invention are additionally or alternatively provided for use in the treatment or prevention of inflammation.

[0040] The pharmaceutical composition is preferably formulated as a unit dosage form, the unit dosage form preferably containing from 0.1 to about 500 mg of polymorph 2.

[0041] The polymorph of the present invention can be used for the treatment or prevention of acute or chronic pain.For example, the polymorph can be used for the treatment of nociceptive pain, such as cutaneous pain, somatic pain, myofascial pain, visceral pain, phantom pain or neuropathic pain.The polymorph of the present invention can also be used in the treatment of headache or migraine.The polymorph can be used alone or in combination with acetaminophen or another NSAID for the treatment of mild chronic pain, or with weak or strong opioids for the treatment of moderate or severe pain.

[0042] The polymorphs of the invention may also be used in the treatment or prevention of neuropathic pain, and may be used in conjunction with one or more antidepressants or antiepileptic drugs, such as gabapentin or pregabalin. Thus, according to another aspect of the invention, a method for treating or preventing pain, inflammation and / or autoimmunity in a human or non-human animal patient is provided. The method includes administering to the patient in need thereof a therapeutically effective amount of the polymorph of the present invention. For human patients, a daily dose of 1.0 mg to 15 g of the polymorph in pure, substantially pure or partially pure form as described in more detail below may be suitably administered. The polymorph may be administered under medical supervision in an amount sufficient to achieve effective pain management. In some embodiments, the daily dose of the polymorph may be titrated to determine such an effective amount. The daily dose may comprise about 5.0 mg to 1 g, typically about 5 mg to 500 mg. In some embodiments, the dose may comprise 10 mg to 100 mg of the polymorph per day. The polymorph may be administered on a regimen of 1 to 4 times per day. The polymorph may be administered parenterally, transdermally, intramuscularly, intravenously, intradermally, intranasally, subcutaneously, intraperitoneally, intracerebroventricularly, intrathecally or rectally. Preferably, the polymorph is administered orally. Optionally, the polymorphs of the present invention may be administered simultaneously, sequentially or separately with at least one opioid analgesic, antidepressant or antiepileptic drug. Alternatively, the polymorphs of the present invention may be administered simultaneously, sequentially or separately with one or more NSAIDs or acetaminophen.

[0043] The polymorphs of the present invention may be used for the treatment or prevention of autoimmunity, i.e. autoimmune diseases. In a preferred embodiment of the present invention, the autoimmune disease is celiac disease, type 1 diabetes, sarcoidosis, systemic lupus erythematosus (SLE), Sjogren's syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis (RA), ankylosing spondylitis, polymyositis (PM), dermatomyositis (DM) or multiple sclerosis (MS).

[0044] The present invention also relates to the use of the polymorph of the present invention in the manufacture of a medicament for use in the treatment or prevention of pain, inflammation and / or autoimmunity.The medicament can be prepared for co-administration with one or more of acetaminophen, another NSAID, an opioid, an antiepileptic drug or an antidepressant.In another embodiment, the present invention provides the use of the polymorph of the present invention in the manufacture of a medicament for use in the treatment of inflammation.

[0045] Advantageously, the polymorphs of the present invention have been found to be effective for reducing or preventing inflammation. The polymorphs of the present invention have also been found to have no or substantially no adverse effects (i.e., within acceptable limits) on the central nervous system.

[0046] In yet another aspect of the present invention, there is provided a pharmaceutical composition for use in treating or preventing pain, inflammation and / or autoimmunity, said composition comprising a pharma- ceutical effective amount of the polymorph of the present invention.The composition may further comprise one or more pharma- ceutical acceptable excipients.In some embodiments, the composition may also comprise acetaminophen, one or more other NSAIDs, one or more weak or strong opioids, antidepressants or antiepileptics.

[0047] The pharmaceutical compositions of the invention may contain the polymorphs of the invention in pure, substantially pure or partially pure form. In some embodiments, the substantially pure form may contain at least 95% by weight of the polymorph, e.g., greater than 96%, 97%, 98%, or 99% by weight of the polymorph.

[0048] The compositions may be formulated as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered dose aerosols or liquid sprays, drops, ampoules, autoinjection devices, suppositories, creams or gels. The compositions may be adapted for oral, enteral, parenteral, intrathecal, nasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Oral compositions (e.g., tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered dose aerosols or liquid sprays, drops, ampoules, autoinjection devices, suppositories, creams or gels) may be suitable for oral, enteral, parenteral, intrathecal, nasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Capsules or wafers are particularly preferred.

[0049] To prepare solid dosage forms such as tablets, the polymorph may be mixed with one or more pharmaceutical excipients, such as conventional tableting ingredients (e.g., corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, or other pharmaceutical diluents (e.g., water), to form a solid pre-formulation composition containing a substantially homogenous mixture of the polymorph such that the polymorph is uniformly dispersed throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules.

[0050] The solid preformulation composition is then subdivided into unit dosage forms of the type described above, each of which may contain from 0.1 to about 500 mg of a polymorph of the invention. Preferred unit dosage forms contain from 1 to 500 mg, e.g., 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 300 mg or 500 mg of a polymorph of the invention.

[0051] When formulated as a tablet or pill, the tablet or pill can be coated or otherwise compounded to provide a dosage form that obtains the advantage of sustained action.For example, the tablet or pill can comprise an inner dosage component and an outer dosage component, the outer dosage component being in the form of a coating that covers the inner component.These two components can be separated by an enteric layer that serves to resist disintegration in the stomach and allows the inner component to pass intact into the duodenum or to be delayed in release.Various materials are known for use in such enteric layers or coatings, including many polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol and cellulose acetate.

[0052] Alternatively, the pharmaceutical compositions of the present invention can be formulated as liquid dosage forms for oral administration or by injection; for example, aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, or flavored emulsions with edible oils (such as cottonseed oil, sesame oil, coconut oil, or peanut oil), as well as elixirs or similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums, such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

[0053] Additionally, the present invention also relates to a method for treating or preventing pain, inflammation and / or autoimmunity in a human or non-human animal patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of Polymorph 2 or a pharmaceutical composition comprising Polymorph 2. In this method, a daily dose of 0.1 mg to 15 g of Polymorph 2 is administered. Polymorph 2 is preferably administered orally.

[0054] The following definitions apply throughout the present specification unless specifically stated otherwise.

[0055] "Treatment" of a disorder or disease may result, for example, in a halt in the progression of the disorder or disease (e.g., no worsening of symptoms) or a slowing of the progression of the disorder or disease (if the halt in progression is only of a transient nature). "Treatment" of a disorder or disease may also result in a partial response (e.g., improvement of symptoms) or a complete response (e.g., disappearance of symptoms) in a subject / patient suffering from the disorder or disease. Thus, "treatment" of a disorder or disease may also refer to an amelioration of the disorder or disease, which may include, for example, a halt in the progression of the disorder or disease or a slowing of the progression of the disorder or disease. The treatment may result in a delay in the progression of the disorder or disease. Such a partial or complete response may be followed by relapse. It should be understood that a subject / patient may experience a wide range of responses to treatment (e.g., exemplary responses as described herein above). Treatment of a disorder or disease may include, in particular, curative treatment (e.g., disease modifying, preferably resulting in a complete response, and ultimately curing the disorder or disease) and palliative treatment (including symptomatic relief).

[0056] The terms "prevention" or "prophylaxis" of a disorder or disease as used herein are also well known in the art. For example, a patient / subject suspected of being susceptible to a disorder or disease may particularly benefit from the prevention of said disorder or disease. The subject / patient may have a susceptibility or predisposition (including but not limited to a genetic predisposition) to the disorder or disease. Such predisposition may be determined by standard methods or assays, for example, using genetic markers or phenotypic indicators. It should be understood that the disorder or disease to be prevented according to the present invention has not been or cannot be diagnosed in the patient / subject (e.g., the patient / subject does not exhibit any clinical or pathological symptoms). Thus, the terms "prevention" or "prophylaxis" include the use of the polymorphs of the present invention before any clinical and / or pathological symptoms have been or can be diagnosed or determined by the attending physician.

[0057] The term "about" preferably refers to ±10% of the indicated numerical value, more preferably ±5% of the indicated numerical value, and in particular to the exact numerical value indicated. For example, the expression "about 100" preferably refers to 100±10% (i.e., 90-110), more preferably 100±5% (i.e., 95-105), and even more preferably to the specific value 100. When the term "about" is used in connection with the endpoints of a range, it preferably refers to a range from the lower endpoint 10% of the indicated numerical value to the upper endpoint +10% of the indicated numerical value, more preferably a range from the lower endpoint 5% to the upper endpoint +5%, and even more preferably a range defined by the exact numerical values ​​of the lower endpoint and the upper endpoint. Thus, the expression "about 10 to about 20" preferably refers to a range of 9 to 22, more preferably a range of 9.5 to 21, and even more preferably a range of 10 to 20. When the term "about" is used in connection with an end point of an open-ended range, it preferably refers to the corresponding range starting from the lower end point 10% or from the upper end point +10%, more preferably from the lower end point 5% or from the upper end point +5%, and even more preferably to the open range defined by the exact numerical value of its corresponding end point. For example, the expression "at least about 10%" preferably refers to at least 9%, more preferably to at least 9.5%, and even more preferably to at least 10%.

[0058] The terms "optional," "optionally," and "may" indicate that the indicated feature may be present, but may not be present. When the terms "optional," "optionally," or "may" are used, the invention specifically relates to both possibilities, i.e., the corresponding feature being present, or alternatively, the corresponding feature being absent. For example, when an element of a composition is indicated as "optional," the invention specifically relates to both possibilities, i.e., the corresponding element being present (included in the composition) or the corresponding element being absent from the composition.

[0059] The term "comprising" (or "comprise", "comprises", "contains", "contains" "comprises," "contains," or "containing" shall mean "particularly comprising," i.e., "including, among other optional elements," unless expressly indicated otherwise or the context contradicts. In addition, the term also includes the narrower meanings of "consisting essentially of" and "consisting of." For example, the term "A comprising B and C" shall mean "A comprising, among other optional elements, B and C," where A may include additional optional elements (e.g., "A comprising B, C, and D" is also included), but the term also includes the meanings of "A consisting essentially of B and C" as well as "A consisting of B and C" (i.e., no other elements besides B and C are included in A).

[0060] Any parameters mentioned in this specification (including, for example, any amounts / concentrations given in "mg / ml" or "% (v / v)" units, and any pH values) are preferably determined at standard ambient temperature and pressure conditions, in particular at a temperature of 25° C. (298.15 K) and an absolute pressure of 1 atm (101.325 kPa).

[0061] It is to be understood that the present invention specifically relates to each and every combination of the features and embodiments described herein (including any combination of the general and / or preferred features / embodiments).

[0062] In this specification, many documents are cited, including patent applications and scientific literature.The disclosures of these documents are not considered relevant to the patentability of this invention, but are incorporated herein by reference in their entirety.More specifically, all mentioned documents are incorporated by reference to the same extent as if each individual document was specifically and individually incorporated by reference. EXAMPLES

[0063] The present embodiments are presented purely for purposes of illustration and not limitation.

[0064] Example 1 - Preparation of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide was prepared as described in WO 2013 / 084238 and US 2011 / 0086910.

[0065] In the first step, 2 g of methyl lactate was reacted with excess benzyl bromide to give 880 mg of (S)-benzyloxymethyl lactate. The reaction was carried out by slurrying sodium hydroxide in THF and cooling to approximately -15°C. The reaction mixture was then allowed to slowly warm to room temperature and stirred for approximately 1-2 hours. The reaction was quenched with saturated ammonium chloride solution and extracted twice with MTBE, followed by removal of the solvent on a rotary evaporator to give a crude oil. The crude product was purified by column chromatography to give pure (S)-2-benzyloxymethyl lactate. The (R)-2-benzyloxymethyl lactate isomer was only present at 0.93%. The yield of this step can be increased by avoiding the presence of moisture in the reaction solution.

[0066] In the second step, 880 mg of (S)-2-benzyloxymethyl lactate obtained in step 1 was reduced using lithium aluminum hydroxide to obtain (S)-2-benzyloxypropylene glycol in 83.8% yield and 98.7% purity. A solution of pure (S)-2-benzyloxymethyl lactate in methylene chloride was stirred, to which was added A solution of lithium aluminum hydroxide was added slowly at approximately 5° C. The reaction was monitored by TLC and quenched very carefully with USP-PW water. No racemization occurred during this process.

[0067] In the third step, (S)-2-benzyloxypropylene glycol was then reacted with methanesulfonyl chloride in methylene chloride in the presence of triethylamine to give the mesylate in 88% yield. The solution from step 2 was stirred in methylene chloride to which methanesulfonyl chloride was added dropwise at <5°C. After the addition was complete, the progress of the reaction was monitored by TLC. The reaction was quenched with USP-PW water. After layer separation, the aqueous layer was back-extracted with methylene chloride. The methylene chloride layers were then combined and washed three times with USP-PW water to remove most of the methanesulfonic acid. No racemization occurred in this step.

[0068] In the fourth step, the mesylate (from step 3) was coupled with SO-benzyltyrosinol to form the bis-protected product in 22.7% yield and 97.4% purity. The reaction was carried out at room temperature using a combination of DMF as the solvent and sodium hydroxide as the base. The reaction was complete after stirring at room temperature for at least 12 hours.

[0069] In the fifth step, 340 mg of the product of step 4 was reduced by hydrogenation in the presence of 10% palladium on carbon catalyst and hydrochloric acid using methylene chloride as a solvent at 50° C. The reaction was completed in approximately 4 hours without racemization to give the desired product in 84.3% yield and 98.9% purity. More specifically, the catalyst was removed by filtration and then the filtrate was concentrated at 33° C. The resulting solid and oil mixture was mixed with ethyl acetate. The resulting slurry was filtered and the solid was washed with ethyl acetate and dried under vacuum at 40-45° C. to give the desired product.

[0070] Example 2 – Preparation of Polymorph 2 (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide (500 mg) was suspended in water (5 mL) and the resulting suspension was shaken and temperature cycled between 40° C. and 25° C. every 4 hours for 72 hours. Excess water was decanted as much as possible using a syringe and needle. The product was then dried. Water was evaporated first at ambient temperature and then at 50° C. under vacuum until a constant weight was achieved.

[0071] Use of the method for the analysis of polymorphs X-ray powder diffraction (XRPD) Approximately 5 mg of sample was gently compressed onto an XRPD zero background single diagonal cut silica sample holder. The sample was then loaded into a Philips X-Pert MPD diffractometer and analyzed using the following experimental conditions: Tube anode: Cu Generator tension: 40kV Tube current: 40mA Wavelength Alpha 1: 1.5406Å Wavelength Alpha 2: 1.5444Å Starting angle [2 θ]: 5 End angle [2θ]: 50 Continuous Scan Representative X-ray data over the range 4 to 40° 2Θ at slower scan speeds Obtained at 1000 points.

[0072] Raman spectroscopy Raman Raman spectra were acquired on a Bruker RFS 100 / S using an excitation wavelength of 1064 nm. The samples were prepared for analysis by placing the material in a sample holder and positioning it in the spectrophotometer.

[0073] Simultaneous thermal analysis (STA) Simultaneous thermal analysis (STA) in this context relates to the simultaneous application of thermogravimetric analysis (TGA) and differential thermal analysis (DTA) in one instrument to one and the same sample.

[0074] Approximately 5 mg of sample was accurately weighed into a ceramic crucible, which was then placed into the chamber of a Perkin-Elmer STA 600 TGA / DTA analyzer at ambient (25°C) temperature. The sample was then heated at a rate of 10°C / min, typically from 25°C to 300°C, during which time the change in weight was monitored as well as the DTA signal. The purge gas used was 20 cm 3 The nitrogen flow rate was 100 / min.

[0075] Differential Scanning Calorimetry (DSC) DSC was investigated on a Netzsch-DSC 204 F1 Phoenix. Approximately 5-6 mg of sample was placed in the DSC pan. The analysis was carried out in a sealed aluminum pan with a pinhole. The sample was heated from 25 to 125 °C at a rate of 10 K / min under nitrogen atmosphere.

[0076] Scanning Electron Microscopy (SEM) Scanning electron microscopy was performed using a Tescan Vega3 Scanning Electron Microscope operating at 15 KV and a slight tilt of 15°.

[0077] Prior to analysis, samples were prepared by adhering them to SEM stubs using double sided carbon impregnated sticky tabs supplied by Agar Scientific.

[0078] The prepared stubs were then coated with 15 nm gold using a Quorum Q150ES sputter coater.

[0079] Gravimetric Vapor Sorption (GVS) Approximately 10 mg of sample was placed into a wire mesh vapor sorption balance pan and loaded onto an "IgaSorp" vapor sorption balance (Hiden Analytical Instruments). The sample was then dried by maintaining a 0% humidity environment until no further weight change was recorded. The sample was then subjected to a ramp profile from 0 to 90% RH in 10% RH increments, maintaining the sample at each step until equilibrium was achieved (99% step completion). Upon reaching equilibrium, the % RH in the instrument was increased to the next step and the equilibration procedure was repeated. After completion of the adsorption cycle, the sample was dried using the same procedure. The weight change during the adsorption / desorption cycle was then monitored, allowing the hygroscopic nature of the sample to be determined.

[0080] Polymorph analysis results The resulting XRPD was as shown in Figure 1. Provided below is a listing of the observed peaks. Table 1 [Table 1-1] [Table 1-2] [Table 1-3]

[0081] 1 H-NMR spectra were measured for (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide before and after crystallization to obtain polymorph 2. These spectra are consistent with each other, indicating that no chemical transformation took place.

[0082] The STA data showed no weight loss, indicating that the sample was not hydrated or solvated. The DTA thermogram (see FIG. 4) shows a sharp melt with an onset of approximately 104.5° C.

[0083] Scanning electron microscopy (SEM) (see FIG. 2) showed that the morphology had a rectangular block crystal habit with grain sizes ranging from 2-10 μm in length and 2-5 μm in width.

[0084] GVS showed that the sample was only slightly hygroscopic with a 0.6% weight gain by 80% RH, indicating that Form 2 was less hygroscopic than Form 1. There was a sharp weight loss at 90% RH for both cycles, which could have been the result of further crystallization of the amorphous content. This resulted in an overall weight loss of about 1% by the end of the two adsorption / desorption cycles, but XRPD did not indicate a change in polymorph.

[0085] Example 3 – Bioavailability of Polymorphs 1 and 2 The study was designed to obtain plasma samples after single-dose oral administration to six dogs, allowing comparison of the bioavailability and pharmacokinetics of the two different polymorphs 1 and 2. A crossover design was used, with three dogs treated according to sequence 1 (polymorph 1 followed by polymorph 2) and three dogs treated according to sequence 2 (polymorph 2 followed by polymorph 1) with a one-week washout period between treatments.

[0086] The concentration-time profiles of both polymorphs were characterized by rapid absorption and a rapid decline in concentrations after peak concentrations; secondary humps in the profiles at and beyond 4 hours suggested entero-hepatic recirculation.

[0087] The maximum observed concentration (C max ) and area under the plasma concentration-time curve (AUC) appeared to be higher after polymorph 2 than after polymorph 1. The least squares (LS) geometric mean estimate of AUC(0-∞) (corrected to a 60.0 mg dose) for polymorph 1 was 13170 h.ng / mL and for polymorph 2 was 20064 h.ng / mL (p=0.0016). max The values ​​(corrected for the 60.0 mg dose) were 4986 ng / mL (polymorph 1) and 11088 ng / mL (polymorph 2), respectively (p=0.0009). Thus, the AUC scale was 1.52 (90% CI: 1.35, 1.71), and the C max A geometric mean ratio (polymorph 2 / polymorph 1) of 2.22 (90%CI: 1.84; 2.70) was obtained for the scale. The results and conclusions from these analyses did not differ if the respective parameters were not corrected for dose differences or if non-extrapolated AUC values ​​were analyzed. These differences between the polymorphs indicate a higher bioavailability of polymorph 2.

[0088] Polymorph 1 was supplied by Quay Pharmaceuticals as a white powder and was stored at ambient temperature in their testing facility. A copy of the analytical data sheet for NRD 135S.E1 Form 1 is shown in FIG.

[0089] Polymorph 2 was prepared as detailed above. A copy of the analytical data sheet for NRD 135S.E1 Form 1 is shown in FIG.

[0090] Each polymorph was prepared as a suspension in a vehicle of 0.5% w / v HPMC K15M / 0.5% w / v Tween® 80 in sterile water.

[0091] Six male beagle dogs (tattoo numbers: Dogs (in-study animal numbers: 4986, 0964, 3611, 2380, 5002 and 1122; in-study animal numbers: 001M, 002M, 003M, 004M, 005M and 006M) were used in this study. Dogs were originally obtained from Marshall Farms USA Inc. (NY, USA) or Envigo RMS and bred for use in scientific procedures. During the pre- and in-study periods, the animals were group-housed in housing appropriate for the species. Before acceptance for use in the study, the animals were subjected to a veterinary examination, which was found to be satisfactory. The holding and testing areas were automatically light cycle and temperature controlled. Light hours were from 0700 to 1900 hours. Temperature and humidity ranges measured during the study were 17.0 to 21.8°C and 23.4 to 83.07%, respectively. All animals were weighed before each dose administration and their weights were recorded. They had access to 200–300 g of a standard laboratory diet of known composition (SDS D3 (E) SQC) per day, except for a fasting period that lasted from the night before dosing until 4 h after dosing. They had free access to good quality mains tap water.

[0092] Formulations were always prepared the morning a dose was to be administered. Each polymorph was prepared as a suspension at a concentration of 12 mg / mL in a vehicle of 0.5% w / v HPMC K15M / 0.5% w / v Tween® 80 in sterile water for injection. The required vehicle volume was added to the appropriate formulation container. The required vehicle volume was calculated as follows: V = (K x D) x 1.25 where: V=final volume K = kg to be administered D=dose volume (mL / kg) 1.25=Excess formulation The required amount of test item was accurately weighed. The test item was weighed using the appropriate conversion factor and the following formula: W = (C × V × 100) / P where: W = required weight (mg) C = target formulation concentration (mg / mL as free base) V=final volume P = purity as free base (polymorph 1 = 98.1%, polymorph 2 = 98.7%)

[0093] The test item was then added in small quantities (under magnetic stirring) into the same container as the dosing vehicle. The formulation was then left under magnetic stirring for 15 minutes. A homogenous suspension was obtained using an Ultraturrax homogenizer at average speed for 15 minutes. The formulation was then left under magnetic stirring until a homogenous suspension was obtained. The pH of the formulation was measured and the value recorded. If the pH was below 3, it was adjusted to a level above 3 by adding 1M NaOH. Once formulation was complete, 3 x 100 μL dose aliquots were obtained. The dose aliquots and any remaining formulation were stored at -80°C until shipping. A summary of each formulation is provided in the table below: Table 2 [Table 2]

[0094] Each group of 3 male dogs received a single oral dose of the polymorph at a target dose level of 60 mg / kg. After a one week washout period, each group of 3 male dogs received the other polymorph. Animals were dosed according to the following table: Table 3 [Table 3] 1 Target value

[0095] For each group, whole blood samples (approximately 1.0 mL) were collected from the jugular vein into NaF / EDTA tubes at the following time points: Pre-dose, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 25 hours after administration

[0096] The times given above are only targets and were tried to be as close as possible. The actual time of sample collection (and administration) was recorded (Table 2) and used in the evaluation of pharmacokinetic parameters. Immediately after collection, blood samples were placed on ice water. As soon as possible, the blood samples were centrifuged (+4°C, 1500g, 10 min). The resulting plasma was divided into two aliquots (vial A: 100 μl plasma, vial B: remaining volume) and stored in appropriately labeled polypropylene tubes in a freezer set to maintain a temperature of -80°C until shipment. All plasma samples, remaining dosage formulations and dose aliquots were stored in a freezer set to maintain a temperature of -80°C until shipment.

[0097] Pharmacokinetic (PK) parameters were estimated using Phoenix pharmacokinetic software using a non-compartmental approach consistent with the oral route of administration. All parameters were generated from the individual concentrations of polymorphs 1 and 2 in plasma. Parameters were estimated using nominal sample collection times relative to the start of each dose administration, within acceptable deviation ranges (±10%). Pre-dose samples below the limit of quantitation (0.5 ng / mL) were assumed to be zero for PK analysis.

[0098] The areas under the plasma concentration versus time curves (AUC) for polymorphs 1 and 2 were calculated using the linear trapezoidal method and linear interpolation. The terminal elimination phase of each concentration versus time curve was identified by visual inspection of the semi-log concentration-time plot. Due to the irregularity of the profile caused by enterohepatic recirculation of the drug in most cases, only the last two observed concentration values ​​could be used in this calculation. The slope of the terminal elimination phase was determined using log-linear regression on unweighted concentration data. Parameters on which the determination of the terminal elimination phase was relied upon were not reported (NR) if the coefficient of determination was less than 0.800 and / or if the extrapolation of the AUC to infinity represented more than 20% of the total area. The parameters listed in Text Table 1 were reported with less than or equal to the significant digits required to describe the time. max All values ​​are reported to three significant figures, except for: Additional parameters were generated automatically by Phoenix, which were not required by the protocol but are maintained in the raw data. Table 4 [Table 4]

[0099] A statistical analysis of the relative bioavailability of the above polymorphs was performed. Calculations were performed in accordance with the FDA Guidance Document: Statistical Approaches to Establishing Bioequivalence as follows:

[0100] AUC(0-∞), AUC(0-t) and C without and with normalization for dose difference after natural log transformation max Values ​​were subjected to a linear mixed-effects model analysis procedure including terms for sequence, subject nested within sequence, period and treatment (polymorph). Furthermore, terminal elimination rate constants and their associated half-lives, clearance (CL / F) and volume of distribution (V / F) were statistically compared using the same analytical modality. All statistical analyses were performed using SAS(登録商標) v9.4; the SAS code is provided in Appendix 3A, while the output of the procedure is provided in Appendix 3B. Least squares mean differences and their 90% CIs of the new versus old polymorphs were estimated using the error variances obtained from the model. Point and interval estimates were back transformed to provide estimates of the ratio of the geometric means of the new versus old. T max For , the median difference of 1 polymorphism versus 2 and its 90% CI were calculated.

[0101] All oral dosing of polymorphs 1 and 2 was performed without incident. No adverse reactions to oral dosing were observed in any of the dosed animals. Body weights and dose administration details are shown in Figure 7. All blood samples were collected at or near (± 6 minutes) the target sample collection time. Actual blood sample collection times are shown in Figure 8. Pharmacokinetic parameters for polymorphs 1 and 2 were generated using data generated from plasma samples collected at the study facility and then shipped to a sponsor representative for bioanalysis. Results of plasma analysis of quality control samples provided assurance to the results reported for the study samples.

[0102] The individual plasma concentration results for Forms 1 and 2 are shown in FIG.

[0103] The mean and individual pharmacokinetic parameter results for Forms 1 and 2 are shown in Figures 10 and 11. The mean concentration versus time profiles following oral administration of Forms 1 and 2 are shown in Figure 12. The individual concentration versus time profiles for Forms 1 and 2 are shown in Figures 13-16.

[0104] After thawing the aliquots reserved from the dosage formulation and from each individual final dose suspension, a homogenous suspension could no longer be obtained and therefore no valid concentration results could be obtained from them.

[0105] The overall pattern of concentration-time profiles was similar between the two polymorphs. Absorption of NRD135S.E1 was rapid after administration of either polymorph. Peak plasma concentrations were often achieved before or already at the time of the first sample (0.25 h), with Ts longer than 0.5 h. max In no case was a trough concentration obtained. The concentration then dropped rapidly, reaching a first trough concentration at approximately 4 hours, which was at most 1 / 10 of the concentration initially achieved. After this time point - as soon as the dogs started to have access to food again - the concentration rose again, forming a secondary (low) peak, which then dropped again. The secondary concentration rise suggests an enterohepatic recirculation of the drug, which has already been noted previously in rats (see, for example, study 12NVMDP1R1), dogs (see study VPT1468), and humans (see study NRD135S.E1.101). Irregularities in the concentration declines prevented accurate estimation of the elimination half-life. However, these final declines were often very similar for both polymorphs in the same animals, providing support for the estimated mean half-life of NRD135S.E1 of around 3-4 hours. Since the extrapolated portion of AUC(0-∞) was small (less than 6%), AUC(0-∞) and, therefore, the disposal parameters CL / F and V / F could still be reliably estimated. Both measures of exposure to the drug appeared to be higher after polymorph 2 than after polymorph 1. The AUC(0-∞) for polymorph 1 (141232) (60.0 mg The least squares (LS) geometric mean estimate for the dose-corrected IL-10 ... max The values ​​(corrected to a 60.0 mg dose) were 4986 ng / mL (polymorph 1) and 11088 ng / mL (polymorph 2), respectively. These differences between the polymorphs indicate that the bioavailability of NRD135S.E1 is higher when polymorph 2 is administered. Polymorph 2 is more thermodynamically stable than polymorph 1, a result that was not predicted.

[0106] The results of the statistical analysis are shown in Table 6. Higher exposure was found for the new (polymorph 2) than for the old (polymorph 1) polymorph. The least squares geometric mean estimate for the AUC extrapolated to infinity (corrected for dose) for the new polymorph, <AUCINF_obs_D>, was 1.52-fold higher than for the old polymorph (90%CI: 1.35, 1.71); this difference was statistically significant (p=0.0016). The difference in maximum concentration was even higher, C for the new polymorph. max The point estimate of the value (corrected for dose differences) was 2.22-fold higher than for the old polymorph (90% CI: 1.84; 2.70). The results and conclusions from the analysis did not differ if the respective parameters were not corrected for dose differences or if non-extrapolated AUC values ​​were analyzed.

[0107] Although there were clear differences in the extent of absorption, the time required to reach maximum concentration (T max There were no differences in absorption rates between the two polymorphs as judged by . There were no differences in the elimination rate constants or half-lives observed following the two polymorphs.

[0108] The concentration-time profiles of NRD135S.E1 after both polymorphs were characterized by rapid absorption and a rapid decline in concentration after peak concentrations; secondary peaks in the profiles at 4 hours and later suggested enterohepatic recirculation.

[0109] The maximum measured concentration (C max ) and the area under the plasma concentration-time curve (AUC) appeared to be higher after polymorph 2 than after polymorph 1. The AUC scale was 1.52 (90% CI: 1.35, 1.71) and C max A geometric mean ratio (polymorph 2 / polymorph 1) of 2.22 (90% CI: 1.84; 2.70) was generated for the scale. The results and conclusions from the analysis did not differ if the respective parameters were not corrected for dose differences or if non-extrapolated AUC values ​​were analyzed. These differences between the forms indicate that polymorph 2 provides a higher bioavailability of NRD135S.E1.

[0110] Although there were clear differences in the extent of absorption, the time required to reach maximum concentration (T max There were no differences in absorption rates between the two polymorphs as judged by . There were no differences in the elimination rate constants or half-lives observed following the two polymorphs.

[0111] A relevant but statistically insignificant effect of sequence is max A sequence effect was observed for , and the ratio of sequence-1 to sequence-2 was estimated as 1.38 (90% CI: 1.06, 1.79). This sequence effect reduces the precision with which exposure differences between the two polymorphs can be inferred.

Claims

[Claim 1] The invention described in the specification.

Images